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Abstract:  The  latest  influenza  A  (H1N1)  pandemic  attracted  worldwide  attention  and 
called  for  the  urgent  development  of  novel  antiviral  drugs.  Here,  seven  tripeptides  are 
designed and explored as neuraminidase (NA) inhibitors on the structural basis of known 
inhibitors. Their interactions with NA are studied and compared with each other, using 
flexible docking and molecular dynamics simulations. The various composed tripeptides 
have respective binding specificities and their interaction energies with NA decrease in the 
order of FRI > FRV > FRT > FHV > FRS > FRG > YRV (letters corresponding to amino 
acid code). The Arg and Phe portions of the tripeptides play important roles during the 
binding process: Arg has strong electrostatic interactions with the key residues Asp151, 
Glu119, Glu227 and Glu277, whereas Phe fits well in the hydrophobic cave within the NA 
active site. Owing to the introduction of hydrophobic property, the interaction energies of 
FRV and FRI are larger; in particular, FRI demonstrates the best binding quality and shows 
potential  as  a  lead  compound.  In  addition,  the  influence  of  the  chemical  states  of  the 
terminal amino acids are clarified: it is revealed that the charged states of the N-terminus 
(NH3
+) and C-terminus (COO
−) are crucial for the tripeptide inhibitory activities and longer 
peptides may not be appropriate. In addition, the medium inhibiting activity by acetylation 
of  the  N-terminus  indicates  the  possible  chemical  modifications  of  FRI.  Experimental 
efforts are expected in order to actualize the tripeptides as potent NA inhibitors in the  
near future. 
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1. Introduction  
At present, influenza is probably the most serious pandemic threat to human health  [1–3]. The 
influenza virus also causes severe morbidity and mortality in poultry as a result of co-infection with 
other pathogens  [4].  Zanamivir and oseltamivir (known as Tamiflu) are two known anti-influenza 
drugs that have been widely used in the chemoprophylaxis and treatment of influenza and stockpiled in 
preparation for pandemic outbreak [4–7]. However, cases of zanamivir or/and oseltamivir resistant 
strains  have  been  reported  [8–10].  It  thus  becomes  very  urgent  to  develop  novel  and  efficient  
anti-influenza drugs in order to prevent and treat influenza infections [2]. 
Neuraminidase (NA) is a major surface glycoprotein of influenza virus that plays a crucial role in 
the release of new viral particles [11]. The inhibition of NA will delay the release of progeny virions 
from infected host cell and thus allow the host immune systems sufficient time to clear them [12]. The 
active sites of NAs are highly conserved across different sub-types of influenza viruses, especially for 
N2 and N9 sub-types (nearly identical) [2,13,14]. Accordingly, NA is an ideal target for the rational 
designs  of  next-generation  anti-influenza  drugs  [15].  Consistent  efforts  have  been  devoted  to  
the  development  of  NA  inhibitors  (NAIs),  using  the  crystal  structures  of  N9  sub-type  NA  
proteins [2,16–19]. Zanamivir and oseltamivir are two representative NAIs that have proven to be 
successful and have been commercialized for human use [5,20,21]. 
Recently, peptides against influenza viruses have shown potential as therapeutic agents [22–25]. It 
was found that the peptides RRKKAAVALLPAVLLALLAP, CNDFRSKTC and NDFRSKT exhibit 
antiviral  properties  and  inhibit  viruses’  attachments  to  cellular  receptors  [22,25].  In  addition,  the  
12-mer peptides (54-N1 and 69-N2) display broad-spectrum inhibitory activities against influenza virus 
through interactions with the NA proteins [23]. However, these peptides are only partially docked into 
the NA active sites and will not form compact binding complexes [23]; moreover, they are not facile to 
synthesize and commercialize, owing to their relatively large molecular sizes. In vitro experiments 
revealed  that  the  inhibiting  activity  of  peptide  NDFRSKT  is  clearly  higher  than  that  of  peptide 
CNDFRSKTC [25], where the contained tripeptide FRS may act as the active center. Accordingly, it is 
of high urgency to discover novel, shorter peptides as lead compounds of the next generation anti-
influenza agents. 
Although  peptides  have  limited  in  vivo  bioavailability,  this  does  not  hamper  the  extensive 
exploitation of peptide-based drugs [26–30]. Some of the top 100 best-selling drugs approved by the 
FDA are peptides [29]. Especially, tripeptides have played an important role in biological processes 
and drug designs [31], of which glutathione (GSH) is probably the most familiar to us [32]. There are 
reports that tripeptides contribute a lot to clinical research, such as thrombin [33], HIV protease [34], 
HCV  protease  [35]  and  immune  systems  [36].  On  the  basis  of  the  evaluations  of  oseltamivir 
carboxylate  (the  active  form  of  oseltamivir)  and  4-(N-acetylamino)-5-guanidino-3-(3-pentyloxy) 
benzoic acid (BA) and three-dimensional information about the NA active site [2,14,37,38], tripeptides Int. J. Mol. Sci. 2010, 11                       
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FRG, FRV, FHV, YRV, FRT, FRS and FRI were designed as NA inhibitors (Figure S1). The seven 
tripeptides,  optimized  with  density  functional  methods,  were  docked  into  the  NA  active  site, 
respectively,  and  their  interaction  mechanisms  were  then  studied  by  explicitly  solvated  molecular 
dynamics (MD) simulations. It was found that FRI has the largest interaction energy and matches 
satisfactorily in the NA active site, which throws new light on the de novo designs of NA inhibitors. 
Around physiological pH values, the N-terminus and C-terminus of FRI are charged, in the forms of 
NH3
+ and COO
−, respectively. How the chemical states of the termini influence the inhibitor binding at 
the NA active site is also an interesting topic that requires attention. In addition, the deprotonation and 
acetylation  at  the N-terminus (-NH2 and -NHCOCH3), as well as the amidation at the C-terminus   
(-CON(CH3)2)  were  considered,  with  their  structures  optimized  at  the  same  level  of  theory.  The 
interaction  mechanisms  of  the  three  structures  with  NA  were  also  studied  by  explicitly  solvated 
flexible docking and MD simulations. The present results can guide synthetic and medicinal chemists 
to discover potent peptide-based antiviral drugs. 
2. Results and Discussion 
As  the  backbone-atom  root-mean-square  deviations  (RMSD)  in  Figure  1  indicate,  all  the  
tripeptide-NA complexes that have been energy-minimized remain stable throughout the 1.0 ns MD 
simulations, consistent with the previous MD results of other NA inhibitors [37–41]. Accordingly, the 
geometric and energetic analyses are made on the average structures of 500~1000 ps MD trajectories, 
where the docked complexes are already at equilibrium. The superposed structures in Figure 2 show 
that the seven tripeptides are in close space at the NA active site, in terms of favorable interaction 
energies  and  geometrical  matching  qualities.  It  means  that  these  tripeptides  occupy  the  identical 
binding pocket of the NA protein. However, their binding poses differ somewhat from each other, 
which will be discussed in the following sections. 
Figure  1.  The  time-evolution  backbone-atom  root  mean  square  deviations  (RMSD)  of 
protein structures in the tripeptide-NA complexes. 
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Figure 2. The tripeptides superposed at the NA active site. The Connolly surfaces of the 
NA active-site (in grey) are created using the InsightII 2005 scripts. The tripeptides are 
represented  by  stick  models.  Ribbon  colors:  Helices  (including  ʱ-,  310-  and  π-helix), 
hydrogen-bonded turns, extended strands and random coils are in red, blue, yellow and 
green, respectively. 
 
2.1. The Tripeptides FRG and FRV as the NA Inhibitors 
On  basis  of  the  structures  of  known  anti-influenza  virus  drugs  such as  oseltamivir carboxylate  
and  BA  [2,14,37,38]  and  the  electrostatic,  steric  and  lipophilic  characteristics  of  NA  active  
sites [1,2,13,23,37,38,42,43], tripeptide FRG was first designed as NA inhibitor. That is, the simplest 
amino acid Gly is at its C-terminus, which is expected to orient towards the Arg triad (Arg118, Arg292 
and Arg371). The guanidino group of FRG is assumed to direct to the acidic sub-site consisting of 
residues Glu119, Asp151 and Glu227. In order to fit the hydrophobic cave of the NA active site, the 
hydrophobic interactions are introduced at the N-terminus using Phe. 
The interaction energy  (Einter) of FRG with NA is calculated at −249.83 kcal mol
−1, where the 
electrostatic rather than vdW interactions are found to play a dominant role (Figure 3). As Figure 4a 
shows, the carboxyl group of FRG has three H-bonds with the positively charged guanidino group of 
residue Arg152. The guanidino group of FRG forms ionic interactions with the negatively charged 
carboxyl groups of residues Glu119, Asp151 and Glu227, with one H-bond formed with each residue. 
The  electrostatic  contributions  (Eele)  of  residues  Glu119,  Asp151,  Arg152  and  Glu227  amount  to 
−92.93, −132.39, −37.21 and −63.39 kcal mol
−1, respectively (Table S1). Nonetheless, the benzene Int. J. Mol. Sci. 2010, 11                       
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group of FRG somewhat flips out from the NA active site. The lack of sidechains in Gly (H atoms) 
does not match with the hydrophobic portion of the NA active site. Accordingly, the C-terminus of 
FRG (Gly) is improved by the G→V mutation. 
Figure  3. The electrostatic (Eele, blue sparse area) and total interaction energies (Einter) 
between NA protein and various tripeptides. 
 
Figure 4. Views of the binding modes of the NA active-site residues with (a) FRG and  
(b) FRV. Key residues are represented by stick models. Tripeptides are represented by ball 
and stick models. The important H-bonds are labeled as dashed black lines.  
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Compared with Gly, the sidechain of Val is more suited to the NA active site (Figure 4). The 
interaction energy (Einter) between FRV and NA is equal to −289.88 kcal mol
−1. The FRV has a value 
40  kcal  mol
−1  larger  than  FRG  (Figure  3).  Similar  to  FRG,  the  electrostatic  rather  than  vdW 
interactions dominate during the binding process. The FRV carboxyl group orients towards the Arg 
triad (Arg118, Arg292 and Arg371) of the NA active site (Figure 4b). The guanidino group of FRV 
shows strong electrostatic effects with residues Glu119, Asp151, Glu227, Glu276 and Glu277, with the 
intergrowth of one H-bond to each of residues Glu276 and Glu277. The corresponding electrostatic 
contributions  (Eele)  are  calculated  at  −73.28,  −125.36,  −68.08,  −103.29  and  −101.73  kcal  mol
−1, 
respectively (Table S1). In addition, the amino group at the N-terminus of FRV forms one H-bond with 
residue Asp151. The benzene group of FRV conduces to the hydrophobic contacts with the NA active 
site. Accordingly, the FRV poses in the NA active site, with a similar manner as the cases of current 
NA  drugs  (oseltamivir,  zanamivir  and  peramivir)  [2,5,14,38,42,44].  Compared  with  FRG,  more 
preference of FRV has been observed. The Arg and/or Phe portions of the tripeptides play crucial roles 
during the binding process, which will be clarified in the following discussions. 
2.2. The Roles of the Arg and Phe Portions in the Tripeptides 
In  order  to  clarify  the  roles  of  the  Arg  and  Phe  portions  in  the  tripeptide  FRV,  another  two 
tripeptides FHV and YRV were designed as NA inhibitors. The interaction energy (Einter) of FHV with 
NA is calculated to be −254.00 kcal mol
−1 (Figure 3). As a result of the disappearance of the Arg 
portion (R→H mutation), the interaction energy (Einter) of FHV is about 36 kcal mol
−1 lower than that 
of FRV. The His portion of FHV does not form any H-bond with the active-site residues and rather 
moves out of the active-site pocket (Figure 5a). In the meantime, the charge transfers of FHV with 
residues  Glu119,  Asp151,  Glu227,  Glu276  and  Glu277  decrease,  in  contrast  to  the  case  of  FRV, 
especially residues Glu276 and Glu277 (Tables S1 and S2). Accordingly, the Arg portion is crucial to 
FRV and responsible for the lower interaction energy of FHV. 
For YRV, the interaction energy (Einter) with NA equals −224.51 kcal mol
−1 and is less than either of 
the tripeptides FRV and FHV (Figure 3). As shown in Figure 5b, the carboxyl group of YRV deviates 
from the Arg triad (Arg118, Arg292 and Arg371), which is quite different from the situations of FRV 
and FHV. Compared with FRV, the electrostatic interactions (Eele) of the YRV guanidino group with 
residues  Glu276  and  Glu277  remarkably  reduce  to  −52.17  and  −69.65  kcal  mol
−1,  respectively  
(Table  S2).  Accordingly,  the  increase  of  polarity  due  to  the  F→Y  mutation  (FRV  to  YRV)  is 
unfavorable  for  the  binding  process.  To  summarize,  the  Arg  and  Phe  portions  of  the  tripeptides, 
especially  the  latter,  are  crucial  to  the  binding  process  and  should  be  reserved  in  the  design  of  
tripeptide inhibitors. Int. J. Mol. Sci. 2010, 11                       
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Figure 5. Views of the binding modes of the NA active-site residues with (a) FHV and  
(b) YRV. Key residues are represented by stick models. Tripeptides are represented by ball 
and stick models. The important H-bonds are labeled as dashed black lines.  
 
2.3. The Improvement of FRV-Based NA Inhibitors 
Among the four tripeptides discussed in Sections 2.1 and 2.2, FRV has the largest interaction energy 
with  the  NA  protein  and  its  binding  pose  is  similar  to  those  of  current  NA  
drugs [2,5,14,38,42,44]. In addition, the Arg and Phe portions of FRV play important roles during the 
binding process. Accordingly, the improvement of tripeptide-based NA inhibitors was next centered on 
the mutations of the C-terminus amino acid Val. In this way, tripeptides FRT, FRS and FRI were 
designed as NA inhibitors. Their binding at the NA active site is shown in Figure 6. 
Owing to the addition of hydrophilic property by the V→T mutation, the interaction energy (Einter) 
of FRT with NA drops to −255.45 kcal mol
−1 (Figure 3). As Figures 4b and 6a show, the maximal 
binding  differences  between  FRT-NA  and  FRV-NA  are  in  that  the  FRT  guanidino  group  orients 
towards Asn346 with two H-bonds formed. In addition, the FRT benzene group is somewhat out of  
the  NA  active  site.  Similar  to  FRV,  the  charge  transfer  interactions  are  observed  between  FRT  
and residues Glu119, Asp151, Glu227, Glu276 and Glu277 (Table S3). However, their electrostatic 
contributions  (Eele)  decrease  remarkably.  Accordingly,  FRV  instead  of  FRT  suits  the  NA  active  
site better.  
The tripeptide FRS is more hydrophilic than FRV (V→S mutation) and meanwhile its spatial size is 
less  than  that  of  FRT.  The  interaction  energy  (Einter)  of  FRS  with  NA  is  calculated  at  
−250.04 kcal mol
−1, somewhat less than those of FRV and FRT (Figure 3). The binding pose of FRS at 
the NA active site is shown in Figure 6b. The FRS carboxyl group is stabilized by residue Arg371, 
with the formation of three H-bonds. The FRS guanidino group forms two H-bonds with each of 
residues  Asp151  and  Glu227.  Compared  with  FRV,  the  tripeptide  FRS  has  less  electrostatic 
interactions with residues Glu119, Asp151, Glu227, Glu276 and Glu277. Especially the electrostatic 
contribution  (Eele)  of  residue  Glu276  is  merely  equal  to  −45.66  kcal  mol
−1  (Table  S3).  More 
importantly, the orientation of the FRS benzene group deviates somewhat from the NA active site. It 
indicates that FRS does not better suit the NA active site than FRV. Int. J. Mol. Sci. 2010, 11                       
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Figure  6.  Views  of  the  binding  modes  of  the  NA  active-site  residues  with  (a)  FRT,  
(b)  FRS  and  (c)  FRI.  Key  residues  are  represented  by  stick  models.  Tripeptides  are 
represented  by  ball  and  stick  models.  The  important  H-bonds  are  labeled  as  dashed  
black lines. 
  
Owing to the increase in spatial size and hydrophobic property introduced by the V→I mutation, 
FRI moves closer to the NA active-site pocket (Figure 6c). The interaction energy (Einter) of FRI equals 
−291.56  kcal  mol
−1  and  is  larger  than  any  of  the  above  six  tripeptides  (Figure  3).  Similarly,  the 
electrostatic rather vdW interactions play a dominant role during the binding process. The FRI carboxyl 
group forms ionic interactions with residues Arg292, Arg371 and Lys432, with two, three and one 
vigorous H-bonds, respectively (Figure 6c). The electrostatic energies (Eele) from residues Arg371 and 
Lys432 amount to −43.88 and −29.62 kcal mol
−1, respectively (Table S3), while these two values are 
very slight in the case of FRV. The FRI guanidino group shows strong interactions with residues 
Glu119 and Glu277, with one and two H-bonds formed, respectively. The FRI benzene group fits 
perfectly with the hydrophobic cave of the NA active site. FRI has complementary properties against 
the geometrical and biophysical environment of the NA active site, which can also be observed in the 
cases of current potent NA drugs; e.g., oseltamivir, zanamivir and peramivir [2,5,14,38,42,44]. Int. J. Mol. Sci. 2010, 11                       
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2.4. The Chemical States of the Termini in Tripeptide FRI  
For all the seven tripeptides, the electrostatic interactions play a dominant role during their binding 
processes (Figure 3), which is consistent with the current NA drugs [2,5,14,38,42,44]. The carboxyl 
groups of the seven tripeptides, except for FRG and YRV, have strong electrostatic interactions with 
the Arg triad (Arg118, Arg292 and Arg371) and should be fully considered in rational drug designs. 
The residues Asp151, Glu119, Glu227 and Glu277 of the NA protein contribute greatly in all the seven 
cases, see the data in Tables S1–S4. In fact, these four residues of the NA protein have already received 
enough attention from rational drug designs [2,14,42]. The catalytic residue Asp151 is crucial to NA 
function and the three glutamic acid residues (Glu119, Glu227 and Glu277) are important to stabilize 
the NA active sites [1,45]. With the low toxicity and viral resistance, the tripeptides throw new light on 
the rational designs of novel anti-influenza drugs [23]. In particular, the interaction energy (Einter) of 
FRI with NA is equal to −291.56 kcal mol
−1 and the largest among the seven tripeptides, which is also 
much  larger  than  that  of  4-(N-acetylamino)-5-guanidino-3-(3-pentyloxy)  benzoic  acid  (BA,  
−160.64  kcal  mol
−1)  [37].  Accordingly,  the  tripeptide  FRI  shows  great  potential  as  an  ideal  
lead compound. 
As  mentioned  in  Section  1,  the  N-terminus  of  FRI  is  in  the  NH3
+  form  around  physiological 
pH values (Figure 4a). Besides, the deprotonated (-NH2) and acetylated (-NHCOCH3) forms are also 
considered  and  designated  as  FRIdep  and  FRIAc,  respectively.  The  deprotonation  causes  the  FRIdep 
benzene group to move out of the NA active-site pocket (Figure 7a), with the interaction energy being 
obviously reduced (Figure 3). The interaction energy (Einter) between FRIdep and NA is summed to  
−138.22 kcal mol
−1; less than half of the normal state (NH3
+). The deprotonation also decreases the 
electrostatic interactions with the NA active-site residues; e.g., residue Glu277, whose electrostatic 
contribution  (Eele)  drops  sharply  from  −108.43  to  −19.89  kcal  mol
−1  (Table  S4).  In  addition,  the  
H-bonds are merely four: two between the FRIdep carboxyl group and residue Arg371 and two between 
the  FRIdep  guanidino  group  and  residue  Glu119  (Figure  7a).  Accordingly,  the  depronation  of  the  
N-terminus NH3
+ group is not favored for the inhibiting activities of the tripeptides. 
When the N-terminus  of FRI is protected by acetylization (-NHCOCH3), the interaction energy 
(Einter) with the NA protein is calculated to be −267.32 kcal mol
−1. It indicates that the acetylization 
also decreases the inhibiting activity but more slightly than the deprotonation (Figure 3). Compared 
with the normal state (NH3
+), the acetylization causes the carboxyl group to move towards residue 
Arg371, with the simultaneous formation of one strong H-bond (Figure 7b). The electrostatic energy 
(Eele) of FRIAc with residue Arg371 increases to −62.66 kcal mol
−1 (Table S4). However, the ionic 
interactions with residue Lys432 do not exist anymore. At the same time, the FRIAc guanidino group 
has less polar contacts with residues Glu227 and Glu277, with one H-bond formed with each of them. 
Accordingly, FRI rather than FRIAc and FRIdep matches satisfactorily with the NA active site. The 
decrease of interaction energies by the acetylization is in good agreement with experiment data that 
long  peptide  chains  may  not  form  compact  binding  complexes  with  the  NA  receptors  [22,23,25]. 
Nonetheless,  FRIAc  still  displays  reasonable  space  orientation  at  the  NA  active  site  and  medium 
inhibiting activity, probably due to that the lost electrostatic binding has been compensated by the 
hydrophobic effects between its acetyl-CH3 and the small pocket of NA active site. This indicates the 
possible prospects of chemical modifications. Int. J. Mol. Sci. 2010, 11                       
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Figure  7.  Views of the binding modes of the NA active-site residues  with (a) FRIdep,  
(b) FRIAc and (c) FRIDMA. Key residues are represented by stick models and tripeptides are 
by ball and stick models. The important H-bonds are labeled as dashed black lines. 
 
Similar to the N-terminus, the C-capped FRI is designed as FRIDMA, in order to explore the roles of 
the C-terminus chemical states during the binding processes. As shown in Figure 3, the C-terminus 
capping  (-CON(CH3)2)  causes  the  interaction  energy  (Einter)  of  FRIDMA  with  NA  to  reduce  to  
−153.29  kcal  mol
−1, about  half of the normal state (COO
−). Compared with FRI, the Phe and Ile 
portions of FRIDMA nearly move out of the active-site pocket. Only the guanidino group of FRIDMA 
forms  two  H-bonds  with  Asp151  and  one  H-bond  with  Glu277  (Figure  7c).  Moreover,  the  ionic 
interactions  with  residues  Arg371  and  Lys432  are  dissolved  as  well  (Table  S4).  Accordingly,  the 
capping of C-terminus (-CON(CH3)2) disrupts the tripeptide interactions with the NA active sites, in 
good agreement with  previous reports that  the charged carboxyl groups (COO
−) are important for 
anchoring inhibitors in the NA active sites by strong electrostatic interactions [37,38,43,46]. It further 
indicates that the long peptides may not be suitable to be designed as NA inhibitors. 
3. Computational Methods 
The docking and molecular dynamics (MD) simulations were performed with the different modules 
implemented under InsightII 2005 software package [47] on Linux workstations.  Int. J. Mol. Sci. 2010, 11                       
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3.1. System Preparations 
The N9 sub-type neuraminidase (NA) crystal structure (PDB code: 1F8B) was recovered from the 
RCSB Protein Data Bank [18]. For convenience, it is named NA throughout this work. The calcium 
ion (Ca
2+) and crystal water molecules near the active site were retained in the protein structure. The 
hydrogen  atoms  were  then  added  on  basis  of  the  expected  charge  distribution  of  amino  acids  at 
physiological  pH  values  [37,38,46,47]. The particular protonation  states  of residues  with titratable 
groups were taken with the aid of the Biopolymer module and manual verification [18,37,38,40,47]. 
Note that the sidechain of residue Asn294 in NA was rotated so that its Oδ1 and Nδ2 atoms of the 
amide group form H-bonds with the nearby Ala246 O and Arg292 Nε2 atoms, which will improve the 
agreement with the overall crystal structure [40]. The NA structure was then neutralized with chloride 
anions [37,38,43,46,48]. The conjugated gradient algorithm was used to optimize the NA structure 
(Discover 3.0 module), with the consistent-valence force-field (CVFF). The convergence criterion was 
set to 0.01 kcal mol
−1 Å
−1. 
All the tripeptides (Figure S1) were optimized with density functional methods [49,50], and the 
details can be found in Supplementary Material. 
3.2. Flexible Docking 
The docking simulations were performed by the protocol used in our previous works [37,38,43,46]. 
The Binding-site module was used to identify the NA active site. Then, the advanced docking program 
Affinity, combining Monte Carlo (MC) and simulated annealing (SA) methods, was used to determine 
the optimal orientations of the tripeptides at the NA active sites [51]. A feature for the semi-flexible 
method is that the ligand and the defined active-site residues were allowed to move freely whereas the 
rest of proteins were held rigid during the docking process. The potential function was assigned using 
the CVFF force-field and the non-bonded interactions were described by the Cell-Multipole approach. 
The solvent effects were considered by solvating the complexes in a large sphere of TIP3P water 
molecules  [52]  with  the  radius  of  35.0  Å.  Chloride  anions  were  added  to  neutralize  the  docked  
systems [37,38,43,46,48]. The docked complexes were selected on basis of interaction energies and 
geometrical  matching  qualities.  The  selected  complexes  were  further  energy-minimized  using  the 
conjugated gradient method until converged to 0.01 kcal mol
−1 Å
−1. 
3.3. Molecular Dynamics (MD) 
The MD simulations were performed on the energy-minimized docked complexes, using the CVFF 
force-field in Discover 3.0 module. The canonical ensemble (NVT) was employed. The simulation 
temperature is 300.0 K (normal temperature), which was controlled by the Langevin thermostat [53]. 
The integration of the classical equations of motion was achieved using the Verlet algorithm. During 
the MD simulations, the inhibitors plus a surrounding sphere of 10.0 Å were allowed to move freely 
whereas the rest were held rigid, consistent with previous works [37,38,46]. The MD trajectories were 
generated using a 1.0-fs time step for a total of 1000 ps, saved at 1.0-ps intervals. The interaction 
energies of tripeptides with NA and the respective residues at the NA active site were calculated by the 
Docking module, over the average structures of 500~1000 ps MD trajectories [51].  Int. J. Mol. Sci. 2010, 11                       
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4. Conclusions 
In this work, a series of tripeptides were explored as potential neuraminidase (NA) inhibitors. Their 
interactions with the NA protein were then studied by flexible docking and molecular dynamics (MD) 
simulations. In addition, the influences were clarified for the chemical states of terminus amino acids. 
This  study  will  guide  synthetic  and  medicinal  chemists  to  discover  potent  tripeptides  as  novel  
anti-influenza virus drugs. 
Based on the structures of known NA inhibitors and the properties of NA active sites, FRG, FRV, 
FHV, YRV, FRT, FRS and FRI were successively designed as NA inhibitors. Details of the binding 
specificity for each of the seven tripeptides at the NA active site are given in the text. The interaction 
energies  decrease  in  the  order  of  FRI  (−291.56  kcal  mol
−1)  >  FRV  (−289.88  kcal  mol
−1)  >  FRT 
(−255.45  kcal  mol
−1)  >  FHV  (−254.00  kcal  mol
−1)  >  FRS  (−250.04  kcal  mol
−1)  >  
FRG  (−249.83  kcal  mol
−1)  >  YRV  (−224.51  kcal  mol
−1).  The  Arg  and  Phe  portions  of  the  
tripeptide-based NA inhibitors are crucial to the binding process: The former has strong electrostatic 
interactions with residues Asp151, Glu119, Glu227 and Glu277, in good agreement with the data of 
commercial NA inhibitors; while the latter perfectly fits the hydrophobic cave of the NA active site. 
Moreover,  the  addition  of  proper  hydrophobicity  facilitates  the  interactions.  Among  the  seven 
tripeptides, FRI best matches  the NA active site and has the largest interaction energy, obviously 
superior  to  the  potential  drug  4-(N-acetylamino)-5-guanidino-3-(3-pentyloxy)benzoic  acid  
(−160.64 kcal mol
−1). Accordingly, it is an ideal lead compound for the designs of tripeptide-based  
NA inhibitors. 
The deprotonation or acetylization of the N-terminus NH3
+ group, as well as the amidation of the 
C-terminus COO
− group causes reduction of the binding qualities. Accordingly, the charged forms of 
the N- and C-termini (i.e., NH3
+ and COO
−) are crucial for the tripeptide inhibitory activities. The 
longer peptide chains may not form compact binding complexes with the NA protein. Nonetheless, 
FRIAc still shows reasonable spatial orientation at the NA active site and medium inhibiting activity, 
indicating the possible chemical modifications. We believe that this work will arouse the interest of 
experimental aspects and result in potent tripeptide-based NA inhibitors in the near future. 
Supplemental Material 
The  details  of  density  functional  methods  and  interaction  energies  of  tripeptides  with  the  NA  
active-site residues can be found as supplemental material. 
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Supplementary Materials 
1. Density Functional Calculations 
As  shown  in  Figure  S1,  seven  tripeptides  FRG,  FRV,  FHV,  YRV,  FRT,  FRS  and  FRI  were 
designed,  which  were  then  optimized  with  B3LYP  density  functional  methods  within  Gaussian03 
software [49,54–59]. The standard 6-31G(d,p) basis set was used [50,60]. The N- and C-termini of 
these tripeptides are protonated and depronated around the physiological pH values; i.e., in the NH3
+ 
and COO
- forms, respectively. In addition, three other states were considered for the tripeptide FRI: the 
N-terminus is neutral (-NH2, see FRIdep in Figure S1h), the N-terminus is acetylated (-NHCOCH3, see 
FRIAc  in  Figure  S1i)  and  the  C-terminus  is  amidated  (-CON(CH3)2,  see  FRIDMA  in  Figure  S1j), 
respectively. The three structures were also optimized with B3LYP/6-31G (d,p) methods. Frequency 
calculations at the same level of theory were performed for all the above structures, confirming that 
they are stable minima on their respective potential energy surfaces (PES) [50]. 
Figure S1. Optimized tripeptide structures at B3LYP/6-31G(d,p) level of theory: (a) FRG; 
(b)  FRV;  (c)  FHV;  (d)  YRV;  (e)  FRT;  (f)  FRS;  (g)  FRI;  (h)  FRIdep;  (i)  FRIAc  and  
(j) FRIDMA. 
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Figure S1. Cont. 
 
Table  S1.  The  vdW,  electrostatic  and  total  interaction  energies  (EvdW,  Eele  and  Einter) 
between FRG, FRV and NA active site residues 
a b. 
  FRG-NA  FRV-NA 
Residue  EvdW  Eele  Einter  EvdW  Eele  Einter 
Glu119  −1.23  −93.23  −94.46  −1.39  −73.28  −74.67 
Ile149  −1.18  −9.19  −10.37  −  −  − 
His150  −8.32  −6.59  −14.91  −  −  − 
Asp151  −2.86  −132.39  −135.25  −5.32  −125.36  −130.68 
Arg152  −2.55  −37.21  −39.76  −  −  − 
Trp178  −  −  −  −3.11  −1.33  −4.44 
Glu227  −1.02  −63.39  −66.41  −0.97  −68.08  −69.05 
Ala246  −  −  −  −5.62  −0.30  −5.92 
Thr247  −  −  −  −3.07  −2.93  −6.00 
Glu276  −0.18  −37.08  −37.26  −0.24  −103.29  −103.53 
Glu277  −1.32  −66.47  −67.79  −0.02  −101.73  −101.75 
Asn347  −2.34  −6.17  −8.51  −4.11  −20.27  −24.38 
a Energy units in kcal mol
−1; 
b Einter < −4.00 kcal mol
−1 are given. 
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Table  S2.  The  vdW,  electrostatic  and  total  interaction  energies  (EvdW,  Eele  and  Einter) 
between FHV, YRV and NA active-site residues 
a, b. 
  FHV-NA  YRV-NA 
Residue  EvdW  Eele  Einter  EvdW  Eele  Einter 
Arg118  −2.58  −13.71  −16.29  −  −  − 
Glu119  −0.07  −57.24  −57.31  −  −  − 
Ile149  −4.16  −1.51  −5.67  −  −  − 
Asp151  −5.74  −57.83  −63.57  −0.48  −126.92  −127.40 
Glu227  −0.36  −14.15  −14.51  −0.88  −63.89  −64.77 
Glu276  −  −  −  −2.33  −52.17  −54.50 
Glu277  −2.80  −5.07  −7.87  −1.12  −69.65  −70.77 
Arg292  −3.49  −28.50  −31.99  −  −  − 
Asn347  −  −  −  −2.70  −6.33  −9.03 
Arg371  1.72  −84.84  −83.12  −  −  − 
Lys432  −0.09  −4.02  −4.11  −  −  − 
a Energy units in kcal mol
−1; 
b Einter < −4.00 kcal mol
−1 are given. 
Table S3. The vdW, electrostatic and total interaction energies (EvdW, Eele and Einter) 
between FRT, FRS, FRI and NA active-site residues a, b. 
  FRT-NA  FRS-NA  FRI-NA 
Residue  EvdW  Eele  Einter  EvdW  Eele  Einter  EvdW  Eele  Einter 
Arg118  −1.04  −20.01  −21.05  −  −  −  −  −  − 
Glu119  −0.40  −30.38  −30.78  −2.75  −65.75  −68.50  −1.82  −56.25  −58.07 
Asp151  3.55  −113.02  −109.47  3.39  −124.73  −121.34  −1.22  −70.93  −72.15 
Glu227  −0.05  −22.80  −22.85  −1.47  −67.11  −68.58  −0.70  −48.77  −49.47 
Ala246  −  −  −  −1.64  −3.41  −5.05  −  −  − 
Thr247  −4.46  −1.39  −5.85  −  −  −  −4.35  −0.46  −4.81 
Glu276  −0.32  −36.13  −36.45  −0.40  −45.66  −46.06  −0.69  −45.56  −46.25 
Glu277  −0.27  −21.88  −22.15  −1.99  −72.05  −74.04  3.25  −108.43  −105.18 
Arg292  −  −  −  −  −  −  −1.34  −6.50  −7.84 
Asn346  0.20  −16.38  −16.18  −  −  −  −  −  − 
Asn347  −4.89  −15.91  −20.80  −3.90  −1.07  −4.97  −  −  − 
Arg371  1.05  −48.40  −47.35  0.94  −30.40  −29.46  1.18  −43.88  −42.70 
Tyr406  −1.52  −14.99  −16.51  −  −  −  −  −  − 
Pro431  −1.78  −2.29  −4.07  −  −  −  −  −  − 
Lys432  −  −  −  1.11  −34.44  −33.33  0.83  −29.62  −28.79 
a Energy units in kcal mol
−1; 
b Einter < −4.00 kcal mol
−1 are given. 
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Table  S4.  The  vdW,  electrostatic  and  total  interaction  energies  (EvdW,  Eele  and  Einter) 
between FRIdep, FRIAc, FRIDMA and NA active-site residues 
a,b. 
  FRIdep-NA  FRIAc-NA  FRIDMA-NA 
Residue  EvdW  Eele  Einter  EvdW  Eele  Einter  EvdW  Eele  Einter 
Glu119   −1.16  −34.45  −35.61  −4.14  −41.99  −46.13  −1.28  −97.43  −98.71 
Ile149   −  −  −  −  −  −  −3.03  −2.78  −5.81 
Asp151   −5.76  −19.80  −25.56  −1.52  −74.80  −76.32  −7.84  −155.98  −163.82 
Trp178   −  −  −  −2.33  −3.54  −5.87  −  −  − 
Glu227   −0.20  −12.64  −12.84  −0.49  −38.62  −39.11  −0.24  −65.95  −66.19 
Ala246   −5.69  0.15  −5.54  −  −  −  −  −  − 
Glu276   −0.55  −7.29  −7.84  −  −  −  −0.90  −82.62  −83.52 
Glu277   −1.37  −19.89  −21.26  −1.83  −32.30  −34.13  −1.33  −94.14  −95.47 
Asn346   −  −  −  −  −  −  −0.50  −3.53  −4.03 
Asn347   −  −  −  −3.01  −1.15  −4.16  −  −  − 
Gly348   −  −  −  −4.61  −7.14  −11.75  −  −  − 
Arg371   0.91  −48.85  −47.94  −7.50  −62.66  −70.16  −  −  − 
Pro431   −  −  −  −2.97  −2.64  −5.61  −  −  − 
Lys432   −  −  −  −0.61  −9.71  −10.32  −  −  − 
a Energy units in kcal mol
−1; 
b Einter < −4.00 kcal mol
−1 are given. 
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